Skip to main content

FDA recall, , Low risk

ValuHealth Extra Strength Pain Relief Acetaminophen

ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg has an incorrect label on the bottle.

What happened

Prodose, Inc. of Ronkonkoma, New York, voluntarily recalled ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg, 40-caplets per bottle, because the inner label on the bottle incorrectly identifies the product as ValuHealth Extra Strength Pain Relief PM. The outer carton label correctly identifies the drug product as ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg. The product was distributed nationwide in the USA and was made in India.

The recall began on October 14, 2026, and was added to the FDA's Enforcement Report on October 26, 2026. Customers were notified by letter.

What to do

The FDA notice gives no instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

Match the UPC and lot code listed under your product.

A UPC is the number printed under a barcode.

  1. ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg

    UPC
    • 8 50026 88900 0
    Lot code
    • P260252

Recall details

Posted by FDA
Recall began
Status
Open
Sold in

Nationwide in the USA

Recalled by
Prodose, Inc.Ronkonkoma, New York
Risk

Low risk

Taking it is unlikely to cause health problems.

FDA Class III recall · How risk is rated

FDA event number
100132
Recall number
D-0081-2027
Recall type
Voluntary: Firm initiated
How the company first told customers
Letter

All recalls from Prodose, Inc.

Timeline

FDA's Enforcement Report is its public list of recalls; FDA posts a recall by adding it there.

  1. Prodose began the recall

  2. FDA posted the recall to its Enforcement Report and rated it Class III (low risk)

  3. Added to Recall Canary

  4. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 31, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)